Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration
Treatment with brolucizumab is effective in patients previously treated with other therapeutic molecules. The best outcomes were achieved in patients who switched therapy to brolucizumab early in their disease. Treatment with brolucizumab in this population demonstrated an acceptable risk profile, with only one intraocular inflammatory event out of 302 intravitreal injections.
Authors
- Ilaria Zucchiatti (ORCID: https://orcid.org/0000-0003-1142-1970)
- Federico Fantaguzzi (ORCID: https://orcid.org/0000-0002-5385-5403)
- Giuseppe Querques (ORCID: https://orcid.org/0000-0002-3292-9581)
- Francesco Bandello (ORCID: https://orcid.org/0000-0003-3238-9682)
- Riccardo Sacconi (ORCID: https://orcid.org/0000-0003-2891-2012)
- Federico Beretta (ORCID: https://orcid.org/0009-0004-8119-9302)
- Stefano Lingardo
Institutions
- Vita-Salute San Raffaele University (IT)
- IRCCS Ospedale San Raffaele (IT)
- Ospedale San Giuseppe (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
Publication Details
- Journal
- Ophthalmology and Therapy
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1007/s40123-025-01141-y
- Citations
- 2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.41